Q3 2025 Mendus AB (publ) Earnings Call Transcript
Key Points
- Mendus AB (FRA:1YG0) reported positive outcomes from their Advanced 2 phase 2A trial in myeloid blood cancers, indicating long-term survival benefits.
- The company is actively expanding its clinical trials, including the AMLM 22 cadence trial and the DIA trial, to address broader patient populations in AML.
- Mendus AB (FRA:1YG0) received a patent from the USPTO for the use of Edensel in ovarian cancer, enhancing their intellectual property portfolio.
- The company has entered into a research collaboration with an international biopharmaceutical company, indicating potential for future partnerships.
- Mendus AB (FRA:1YG0) is preparing to enter the chronic myeloid leukemia market, which represents a large and growing patient population with unmet medical needs.
- Mendus AB (FRA:1YG0) anticipates additional trial costs in 2026, leading to staff reductions, including management team members.
- The company's cash flow remains negative, with a cash position expected to last only until the beginning of 2026.
- There is a need for larger patient populations in future trials, which may increase complexity and costs.
- The company is facing challenges in adapting to the evolving AML treatment landscape, requiring strategic adjustments.
- Mendus AB (FRA:1YG0) has not significantly changed its time to market, potentially delaying revenue generation from new treatments.
Welcome to Mendu's Q3 report 2025 presentation. During the questions and answer session, participants are able to ask questions by dialing 5 on their telephone keypad. Now I will hand the conference over to the speakers, CEO Eric Manting and CFO Lattafirm. Please go ahead.
()-
Good afternoon everybody. Good morning for those of you from the US joining and welcome to the Q3 financial business update from Mendez.
Of the company, we have to show our disclaimer. It's also available on our website.
The Q3 of 2025 has mainly been focusing on the progress in myeloid blood cancers.
It means we have followed up our Advanced 2 phase 2A trial and have indicated a positive outcome now at 48 months median follow-up.
But also those data give us a lot of confidence about the potential of the product in the broader AML setting.
We have started and the trial is ongoing and recruiting the AMLM 22 cadence trial together with the Australasian
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
